R&D expense · 2011–2025
Teva Pharmaceutical Industries R&D expense
$1.0B+1.5% · FY2025
Teva Pharmaceutical Industries (TEVA) reported $1.0B in R&D expense for fiscal 2025, +1.5% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $1.0B | +1.5% | Open → |
| FY20242024-12-31 | $998M | +4.7% | Open → |
| FY20232023-12-31 | $953M | +872.4% | Open → |
| FY20222022-12-31 | $98.0M | −89.9% | Open → |
| FY20212021-12-31 | $967M | −3.0% | Open → |
| FY20202020-12-31 | $997M | −1.3% | Open → |
| FY20192019-12-31 | $1.0B | +786.0% | Open → |
| FY20182018-12-31 | $114M | −34.9% | Open → |
| FY20172017-12-31 | $175M | −58.5% | Open → |
| FY20162016-12-31 | $422M | +1,105.7% | Open → |
| FY20152015-12-31 | $35.0M | +$35.0M | Open → |
| FY20142014-12-31 | $0 | −100.0% | Open → |
| FY20132013-12-31 | $5.0M | −93.2% | Open → |
| FY20122012-12-31 | $73.0M | +386.7% | Open → |
| FY20112011-12-31 | $15.0M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +35.1%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Teva Pharmaceutical Industries R&D expense |url=https://companiesranked.com/en/company/teva-pharmaceutical-industries/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Teva Pharmaceutical Industries R&D expense. CompaniesRanked. https://companiesranked.com/en/company/teva-pharmaceutical-industries/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-teva-pharmaceutical-industries-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Teva Pharmaceutical Industries R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/teva-pharmaceutical-industries/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-034532 · February 3, 2026
{{cite web |title=Teva Pharmaceutical Industries R&D expense — 10-K (0001193125-26-034532) |url=https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-03}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.